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Peptide–MHC (pMHC) multimers have become the “gold standard” for the detection 
and isolation of antigen-specific T-cells but recent evidence shows that normal use of 
these reagents can miss fully functional T-cells that bear T-cell receptors (TCRs) with 
low affinity for cognate antigen. This issue is particularly pronounced for anticancer 
and autoimmune T-cells as self-reactive T-cell populations are enriched for low-affinity 
TCRs due to the removal of cells with higher affinity receptors by immune tolerance 
mechanisms. Here, we stained a wide variety of self-reactive human T-cells using regu-
lar pMHC staining and an optimized technique that included: (i) protein kinase inhibitor 
(PKI), to prevent TCR triggering and internalization, and (ii) anti-fluorochrome antibody, 
to reduce reagent dissociation during washing steps. Lymphocytes derived from the 
peripheral blood of type 1 diabetes patients were stained with pMHC multimers made 
with epitopes from preproinsulin (PPI), insulin-β chain, glutamic acid decarboxylase 65 
(GAD65), or glucose-6-phospate catalytic subunit-related protein (IGRP) presented by 
disease-risk allelles HLA A*02:01 or HLA*24:02. Samples from ankylosing spondylitis 
patients were stained with a multimerized epitope from vasoactive intestinal polypep-
tide receptor 1 (VIPR1) presented by HLA B*27:05. Optimized procedures stained an 
average of 40.5-fold (p = 0.01, range between 1.4 and 198) more cells than could 
be detected without the inclusion of PKI and cross-linking anti-fluorochrome antibody. 
Higher order pMHC dextramers recovered more cells than pMHC tetramers in parallel 
assays, and standard staining protocols with pMHC tetramers routinely recovered less 
cells than functional assays. HLA A*02:01-restricted PPI-specific and HLA B*27:05-
restricted VIPR1-specific T-cell clones generated using the optimized procedure could 
not be stained by standard pMHC tetramer staining. However, these clones responded 
well to exogenously supplied peptide and endogenously processed and presented epi-
topes. We also showed that anti-fluorochrome antibody-conjugated magnetic beads 
enhanced staining of self-reactive T-cells that could not be stained using standard 
protocols, thus enabling rapid ex vivo isolation of autoimmune T-cells. We, therefore, 
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conclude that regular pMHC tetramer staining is generally unsuitable for recovering 
self-reactive T-cells from clinical samples and recommend the use of the optimized 
protocols described herein.
Keywords: peptide–MHC multimer, tetramer, dextramer, autoimmune disease, T-cell, type 1 diabetes, ankylosing 
spondylitis, cancer epitope
at the other end of the spectrum and can have TCRs that bind 
very weakly (KD >  150 μM) [(10, 15) and unpublished data] 
(Figure 1).
Although TCR engagement with cognate pMHC is short-
lived, this interaction can be stabilized by the “avidity effect” 
afforded by incorporating multiple pMHC on a single molecule 
(17). This effect was originally taken advantage of by combin-
ing soluble biotinylated pMHC with fluorochrome-conjugated 
streptavidin. The resultant pMHC tetramers can bind stably 
to cognate T-cells within peripheral blood mononuclear cells 
(PBMC) to allow detection and phenotyping of antigen-specific 
T-cells directly ex vivo. Since their initial adoption in 1996 (18), 
pMHC tetramers have been used in many thousands of studies 
and it is no exaggeration to say that they have revolutionized the 
study of antigen-specific T-cell populations in ex vivo samples 
(19). Various pMHC multimerization platforms have been 
utilized, most of which are commercially available [reviewed in 
Ref. (17, 20)]. In 2007, we described how the affinity required for 
stabilization of pMHC tetramer binding was considerably higher 
than that required for T-cell activation (21). Consequently, stand-
ard pMHC tetramer staining fails to reveal fully functional T-cells 
that bear TCRs below the limits of detection. This deficiency 
precipitated the development of various methodologies aimed at 
lowering the TCR affinity threshold for pMHC multimer staining 
(summarized in Table 1).
We currently utilize an optimized pMHC multimer staining 
procedure that incorporates two simple, inexpensive, broadly 
applicable improvements that can be used with pMHCI and 
pMHCII reagents and aids staining in all species tested to date, 
including human, mouse, monkey, and pig (32–35). The first 
of these improvements involves inclusion of 50nM Dasatinib, a 
protein kinase inhibitor (PKI), to prevent TCR downregulation 
(32). In addition, we include an anti-fluorochrome antibody 
(Ab) to cross-link pMHC multimers at the T-cell surface. Such 
cross-linking can result in substantial improvements in pMHC 
multimer staining by stabilizing binding and limiting dissocia-
tion during washing steps (33). Here, we apply standard pMHC 
tetramer staining and an optimized protocol including PKI and 
cross-linking Ab (PKI + Ab) when staining clinical samples with 
a wide range of self-epitopes relevant to type 1 diabetes (T1D) 
and ankylosing spondylitis. The optimized protocol was found 
to be up to two orders of magnitude more effective, in terms of 
cell numbers recovered and brightness of staining, than parallel 
staining in the absence of PKI + Ab. Importantly, T-cell clones 
isolated by optimized pMHC multimer staining could not be 
stained with cognate antigen in the absence of PKI + Ab despite 
being fully functional, i.e., able to recognize targets in the pres-
ence of exogenously supplied peptide or endogenously processed 
and presented antigen.
INTRODUCTION
Conventional T-cells orchestrate the immune response to 
patho gens by recognizing foreign protein antigens in the 
form of peptides presented at the cell surface bound to MHC 
molecules. The key to recognition lies in the heterodimeric αβ 
T-cell receptor (TCR) which, in concert with either the CD4 or 
CD8 coreceptor, engages peptide–MHC (pMHC) to produce an 
intracellular transduction cascade that results in T-cell activa-
tion (1–3). TCR–pMHC binding parameters are selected in 
the thymus via recruitment of the signal-initiating kinase Lck, 
which is sequestered by the intracellular tails of CD4 and CD8 
(4). These coreceptors bind to sites on MHC class I and class II, 
respectively, that are distinct from the TCR-docking platform 
thereby enabling formation of TCR–pMHCI-CD8 or TCR–
pMHCII-CD4 quadripartite complexes (3, 4). The privileged 
delivery of Lck to the cytoplasmic side of the TCR/CD3 complex 
by the T-cell coreceptors ensures that TCRs are MHC-restricted 
(5–7) and selects the TCR–pMHC dwell time that permits 
onward thymic development and release into the periphery 
(4). T-cells bearing TCRs that do not interact with self pMHC 
die by neglect in the absence of a positive selection signal (8). 
At the other extreme, cells bearing TCRs that bind strongly to self 
pMHC, and thereby have potential to react to self, are eliminated 
from the pool of developing T-cells (8). This central tolerance 
mechanism ensures that T-cells with TCRs that interact strongly 
with self-peptides do not enter the peripheral tissues and, in 
conjunction with peripheral tolerance mechanisms, explains 
why self-reactive TCRs bind with lower affinity, and with shorter 
dwell times than TCRs specific for foreign, pathogen-derived 
peptides (9, 10). Indeed, the best anti-pathogen TCRs tend to 
bind with TCR affinities with dissociation constants (KDs) in 
the range of 0.1–10 µM by surface plasmon resonance (SPR) 
whereas self-reactive TCRs isolated from anticancer and 
autoimmune T-cells bind with much weaker affinities (KD 
20–500  µM) (9–11). Functional assays using modified TCRs 
with enhanced affinities indicate that the most sensitive T-cells 
tend to have TCRs that bind with KDs between 0.1 and 3 µM, 
which sit at the higher end of the natural anti-pathogen TCR 
affinity range (9–11). Further engineered increases in TCR affin-
ity are generally detrimental as they are thought to impede the 
serial triggering of many TCRs by a single agonist pMHC and 
can result in recognition of self-peptides (12, 13). Thus, T-cell 
development imposes a dwell time “window” on the TCRs of 
peripheral T-cells that is of sufficient duration to allow TCR trig-
gering but short enough to enable serial triggering of multiple 
receptors by each agonist pMHC (14). In general, anti-pathogen 
TCRs sit at the stronger end of this affinity window, followed by 
anticancer TCRs (1, 9, 10), whereas autoimmune TCRs reside 
TABLE 1 | Methods for improving peptide–MHC (pMHC) multimer staining.
Method Mechanism of action Pros Cons Reference
Higher order 
multimers
Increased avidity due to more TCR 
interactions per molecule
Detects T-cells with lower affinity TCRs. Can carry 
more fluorochome resulting in brighter staining
More expensive and more 




Enhances rather than inhibits TCR–pMHC 
interactions
Works for MHCI and MHCII None known (24–27)
Enhanced MHC–CD8 
interaction
Mutation of the MHC at the CD8 binding site 
that stabilizes TCR–pMHCI interactions
Allows stable interaction with lower affinity TCRs Only applicable to MHCI and 





Enhances TCR–pMHCII interactions Can substantially enhance staining of CD4 T-cells  
with multimerized MHCII
Only applicable to MHCII. 
May differentially favor TCRs 




Prevents TCR triggering and downregulation Very inexpensive. Applicable to any pMHC multimer 
in all species tested to date
None known (32)
Cross-linking Ab Stabilizes bound pMHC multimer during 
washing steps
Very inexpensive. Applicable to any pMHC multimer 
in all species tested to date
None known (33)
Only the methods boxed in red were utilized in this study.
FIGURE 1 | Self-reactive T-cells have low-affinity T-cell receptors (TCRs). Anti-pathogen TCRs tend to bind to cognate Peptide–MHC (pMHC) with relatively high 
affinity (KD < 20 μM). The rigors of central tolerance ensure that autoimmune TCRs bind with much weaker affinity. Anticancer TCRs tend to sit between these two 
extremes. This schematic depicts a general overview of what is normally observed. A minority of TCRs do not obey these general rules. Cancer TCRs that bind to 
unstable pMHC have been described can have higher affinites (KD ~ 15 µM) (16). TCRs specific for cancer neoantigens (non-self) may behave more like pathogen-
specific TCR. The arrows at the top indicate the rough affinity detection threshold of TCRs amenable to staining with standard pMHC multimer staining and an 
optimized procedure including protein kinase inhibitor and antibody cross-linking. Optimized staining with pMHC tetramers is believed to detect almost all 
antigen-specific T-cells. An optimized dextramer is only required when staining the very weakest of functional autoimmune T-cells.
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MATERIALS AND METHODS
Patient Material and Ethical Approval 
Statement
Cryopreserved PBMCs from patients with T1D were obtained 
with the approval of a national research ethics committee, and 
informed consent was obtained from all participants. Ankylosing 
spondylitis patients were recruited locally from the clinic (Cardiff 
Regional Experimental Arthritis Treatment and Evaluation 
Centre) and anonymized whole blood used for preparation of 
PBMCs. Patients gave informed consent in accordance with the 
Research Ethics Committee for Wales (12/WA/0045). PBMC 
TABLE 2 | T-cell epitopes used in this study.
HLA-restriction Peptide sequence Protein origin (and residues) Disease relevance Reference
A*02:01 NLVPMVATV Cytomeglavirus (CMV) pp65 (495–503) CMV infection (control) (40)
A*02:01 ILAKFLHWL Human telomerase reverse transcriptase  
(hTERT) (540–548)
Not natural (control) (41)
A*02:01 ALWGPDPAAA Preproinsulin (PPI) (15–24) Type 1 diabetes (T1D) (42)
A*02:01 VMNILLQYVV Glutamate decarboxylase 65 (GAD65) (114–123) T1D (43)
A*02:01 VLFGLGFAI Islet-specific glucose-6-phosphatase catalytic  
subunit-related protein (IGRP) (265–273)
T1D (44)
A*02:01 MVWESGCTV Islet Antigen-2 (IA-2) (795–805) T1D (45)
A*02:01 HLVEALYLV Insulin-β chain (10–18) T1D (46)
A*02:01 NLSALGIFST Insulin-like growth factor 2 mRNA binding protein 2 
(IMP2) (367–376)
Cancer Unpublished
A*24:02 LWMRLLPLL PPI (3–11) T1D (47)
B*27:05 KRWILLGLNK HIV p24 gag (263–27) HIV infection (control) (48)
B*27:05 RRKWRRWHL Vasoactive intestinal polypeptide receptor 1  
(VIPR1) (400–408)
Ankylosing spondylitis (49)
B*27:05 DRASFIKNL Collagen type VI α2 subunit (114–122) Ankylosing spondylitis (50)
Shaded based on HLA restriction.
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were obtained from a further HLA B*27:05 ankylosing spondy-
litis patient diagnosed at the Institute of Rheumatology, Russian 
Academy of Medical Sciences, Moscow, Russia, in accordance 
with modified New York criteria (36). This patient gave written 
informed consent prior to enrolling in the study. The study was 
approved by the local ethical committee of Pirogov Russian 
National Research Medical University, Moscow, Russia. This 
patient has been the subject of several previous studies (37–39).
Peptide Epitopes
The peptide epitopes and their restricting HLA and disease 
relevance are listed in Table 2.
T-Cell Culture and Cloning
T-cell clones and lines were cultured in T-cell media (RPMI-1640, 
10% fetal bovine serum (FBS), 2 mM l-glutamine, 100 U/mL 
penicillin, 100  µg/mL streptomycin, 10  mM HEPES buffer, 
0.5× non-essential amino acids, and 1 mM sodium pyruvate, 
all from Life Technologies, Carlsband, CA, USA) supplemented 
with 200 IU of IL-2 (Aldesleukin, Proleukin, Prometheus, San 
Diego, CA, USA) and 25  ng/mL human IL-15 (Peprotech, 
Rocky Hill, NJ, USA). T-cells were stimulated for expansion 
every 2–5 weeks with irradiated (3,000–3,100 cGy) allogeneic 
PBMCs from three donors and 1–2 µg/mL of phytohemaggluti-
nin (Alere, Thermo Scientific, Walthan, MA, USA). T-cell clones 
were procured by limiting dilution as previously described (51) 
and expanded as described above. T-cells were cultured for a 
minimum of 2 weeks post-restimulation before being used for 
experiments.
Generation of Immortalized B-Cells
Lymphoblastoid cell lines (LCLs) were created from PBMCs by 
incubation with Epstein–Barr virus (EBV) containing superna-
tant from the B95-8 cell line. Media (36–48 h of culture) from 
Cotton-top Tamarin monkey B95-8 cell line (European Collection 
of Authenticated Cell Cultures, catalogue number 85011419) at 
80–90% confluence was harvested, centrifuged at 400 g for 5 min, 
0.22-µm filtered, and stored at -80°C. PBMCs (1–5 × 106) were 
cultured in 1 mL R10 medium (RPMI, 10% FCS, l-glutamine, 
penicillin, and streptomycin) with 1 mL of B95-8 supernatant 
with 4 µg/mL of cyclosporin A (Sigma-Aldrich, St. Louis, MO, 
USA). Cells were passaged as required, and cyclosporin A treat-
ment continued for 2 weeks.
Expressing Transgenic Self-Proteins
A K562 cell line expressing HLA A*02:01 and preproinsulin was 
generated and cultured as previously described (42). Patient 
LCLs were made to express vasoactive intestinal polypeptide 
receptor 1 (VIPR1) or the α2 chain of collagen type VI. Codon 
optimized full-length VIPR1 (UniProtKB P32241) or COL6A2 
(UniProtKB P12110) cDNAs were synthesized (Genewiz, 
South Plainfield, NJ, USA) and cloned into the third generation 
lentiviral transfer vector pELNS (kindly provided by Dr. James 
Riley, University of Pennsylvania, PA, USA). The pELNS vector 
contains a rat CD2 (rCD2) marker gene separated from the gene 
of interest by a self-cleaving 2A sequence. Lentiviral particle 
production by calcium chloride transfection and rCD2-based 
purification of lentivirally transduced cells were performed as 
previously described (52).
pMHC Multimers and Flow Cytometry
Monomeric pMHCs were generated in-house (53) and used 
to assemble tetramer and dextramers as previously described 
(22, 33). Premium grade R-Phycoerythrin conjugated strepta-
vidin (SA) was purchased from Life Technologies (catalog 
number S21388). R-Phycoerythrin conjugated SA dextramer 
backbone was sourced from Immudex Limited (Copenhagen, 
Denmark). Tetramers and dextramer were stored at 4°C in the 
dark with added protease inhibitors (1:100 of set 1, Merck, 
London, UK) and used within three days of being assembled. 
Clones/lines/PBMCs were harvested from culture or recently 
defrosted cells, washed (400 g, 5 min), counted, and placed in 
5mL polypropylene tubes suitable for flow cytometry. Typically, 
2 × 104 of a clone, 1 × 105 of a line, or 3 × 106 PBMCs were 
used for staining. The cells were washed with FACS buffer 
(PBS + 2% FBS).
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Optimized pMHC Multimer Staining
An overview of the optimized staining protocols used in this study 
can be found in Figure S1 in Supplementary Material. Cells were 
pretreated with the PKI (50 nM) Dasatinib (Axon Medchem, VA, 
USA), for 5–60 min (typically 30 min) at 37°C in 100 µL:50 µL 
of residual fluid and 50 µL of 2× PKI (100 nM) in PBS. PKI was 
stored as 1 mM single use DMSO stocks at -80°C. The flexibility 
of the incubation time needed for PKI allows either a “fast-track” 
staining protocol (5 min with PKI) to be performed or allows 
time to prepare other reagents needed for the assay (<60 min 
with PKI). PE-conjugated tetramers or dextramers were spun 
in a microfuge to remove aggregates (full speed for 1 min), and 
then 0.5 µg (with respect to pMHC component) added directly 
to each sample without washing or pre-chilling, followed by 
incubation for 30 min on ice and in the dark. Cells were washed 
with 3 mL of FACS buffer (700 g, 3 min) and 0.5 µg (10 µg/mL) 
of mouse anti-PE unconjugated Ab (clone PE001, BioLegend, 
London, UK) added to each sample for 20 min on ice and in the 
dark. Whereas we used PE-conjugated pMHC multimers for this 
study, other fluorochrome, for instance allophycocyanin (APC), 
conjugated tetramers or dextramers can also be used with the 
optimized protocol, by matching the anti-fluorochrome Ab to the 
pMHC multimer, as previously described (53). Cells were washed 
with 3 mL of PBS (700 g, 3 min) to remove residual serum and 
incubated for 5 min at RT with 2 µL of LIVE/DEAD fixable dead 
cell stain (Vivid; Life Technologies) that had been diluted 1:40 
using PBS. Ab cocktails to detect surface markers were added 
directly to each sample without washing. For clones, anti-CD8-
APC or -APC Vio770™ (clone BW135/80, Miltenyi Biotech) 
and anti-CD3-peridinin chlorophyll (clone BW264/56, Miltenyi 
Biotech) were used. For lines and PBMCs, anti-CD19-pacific 
blue (PB) (clone HIB19, BioLegend) and anti-CD14-PB (clone 
M5E2, BioLegend) Abs were also included. Cells were washed 
with 3 mL of FACS buffer and resuspended in 50 µL of FACS 
buffer. Although not performed in this study, samples can be fixed 
with 2% paraformaldehyde (PFA) by washing with 3 mL of PBS, 
incubating with 50 µL of 4% PFA (added to the 50 µL of residual 
PBS left after washing) on ice for 20 min in the dark, washing 
again with 3 mL of PBS, decanting, then storing at 4°C in the 
dark ready for flow cytometry the following day. Samples were 
vortexed throughout the staining protocol, both prior and post 
the addition of reagents.
Standard pMHC Staining
The standard protocol was performed in the same manner as the 
optimized, but without addition of PKI or anti-PE Ab. For the 
comparative purpose of this study, cells were mock treated with 
PKI by the addition of 50 µL of PBS.
Flow Cytometry and Analysis
For acquisition cells were run a BD FACS Canto II (BD 
Biosciences) and for sorting on a BD FACS Aria (BD Biosciences) 
run by Central Biotechnology Services (Cardiff University, 
Wales, UK). Sequential gating strategy for tetramer and dex-
tramer analyses; Gate 1: lymphocytes; Gate 2: single cells; Gate 3: 
CD3+ Vividneg CD19neg CD14neg cells; then displayed as dot plots 
(CD8 versus tetramer or dextramer) or histograms of tetramer 
or dextramer fluorescence. Smoothed zebra plots with outliers 
shown as large dots were used for the display of dot plots. FlowJo 
software (TreeStar, Inc., Ashland, OR, USA) was used to analyze 
the data.
Magnetic Bead Enrichment
Peripheral blood mononuclear cells were treated and incubated 
with PKI and dextramers as above (Figure S1 in Supplementary 
Material for protocol schematic). Cells were washed in ice cold 
MACS buffer (D-PBS without calcium and magnesium ions, 0.5% 
bovine serum albumin (both Sigma-Aldrich), and 2 mM EDTA, 
pH 7.2–7.5). Anti-PE magnetic microbeads were used accord-
ing to the manufacturer’s instructions, whereby 80 µL of MACS 
buffer and 20 µL of beads were used per 1 × 107 cells, with no 
scaling down for lower cell numbers. Positive cells were collected 
by centrifugation (400 g for 5 min) and incubated overnight in 
a single well of a 96-U-well plate, in T-cell media. Cells were 
expanded in the same well with PHA and allogenic PBMCs, as 
described above.
Functional Assays
TNF Processing Inhibitor-0 (TAPI-0) Assay
Cells were harvested from culture washed with R0 (as for R10 but 
with no FBS) and rested overnight in R5 media (as for R10 but 
with 5% FBS). Resting ensured minimal background activation 
of the T-cells. On the day of activation assay, cells were harvested, 
and 2–5 × 104 cells were incubated with 30 µM TAPI-0 (Sigma-
Aldrich) (54) anti-TNF-PE-Vio770™ (clone cA2, Miltenyi 
Biotech) and anti-CD107a-PE (clone H4A3, BD Biosciences) 
Abs in well(s) of a 96U-well plate. For peptide presentation, 
autologous LCLs were used for clonal T-cells, and T-cell to T-cell 
presentation used for T-cell lines. The cells were incubated for 
4–5 h at 37°C then stained with Vivid and Abs for CD3 and/or 
CD8, as above.
Enzyme-Linked Immunosorbent Assay (ELISA)
Prior to assay, T-cell clones were rested overnight in R5. Clonal 
CD8 T-cells (3 × 104 per well) were incubated overnight at 37°C. 
Autologous LCLs or T2 cells (ATCC CRL-1992) were used as anti-
gen presenting cells for clonal T-cells. Supernatants were harvested 
the following morning and assayed for macrophage inflammatory 
protein (MIP)-1β by ELISA according to the manufacturer’s 
instructions (R&D Systems, Minneapolis, MN, USA).
RESULTS
Superior Detection of Pancreatic Peptide-
Specific T-Cells With an Optimal Tetramer 
Staining Protocol
Four HLA class I alleles have been linked to T1D, namely 
HLAs A*02:01, A*24:02, B*18:01, and B*39:06 (55). Due to the 
prevalence of some of these alleles in the general population, 
the vast majority of T1D patients carry either HLA A*02:01 or 
HLA A*24:02 so these alleles were chosen for this study. Several 
pancreatic β-cell-specific epitopes that are presented by these 
alleles have been defined (42, 44, 47, 56, 57). Purified CD8 T-cells 
FIGURE 2 | Enhanced detection of autoimmune T-cells from a type I diabetic patient using optimal tetramer staining techniques. (A) Standard and optimal tetramer 
staining approaches to detect antigen-specific T-cells. Optimal staining uses the protein kinase inhibitor (PKI) Dasatinib to treat T-cells before staining with tetramer 
and then an unconjugated anti-fluorochrome Ab. We have previously described the use of conjugated secondary antibodies to bind the primary antibody, adding 
further fluorescence to peptide–MHC multimers labeled T-cells, but for the purpose of this study only the primary cross-linking antibody was used. T-cell receptor 
(TCR). (B) Sorted CD8 T-cells from a HLA A*02:01+ patient with type I diabetes were stimulated with a peptide from CMV (pp65495–503, NLVPMVATV) and then 
stained 2 weeks later with irrelevant (hTERT540–548, ILAKFLHWL) or CMV tetramers using standard conditions. (C) From the same patient in (B) CD8 T-cells were 
stimulated with peptide (HLVEALYLV) from insulin-β chain10–18 or glutamate decarboxylase 65 (GAD65114–123, VMNILLQYVV). 2 weeks post-stimulation reactivity 
toward the respective peptide (100 nM) was assessed by co-incubation with TAPI-0 and detection of CD107a and TNF (left panel). The T-cell lines were stained with 
PE-conjugated irrelevant (as above) and respective autoimmune tetramers using standard or optimal conditions (right panel). The percentage of cells residing in each 
gate are shown.
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from an HLA A*02:01+ type I diabetes patient were stimulated 
with peptides from CMV, GAD65, IGRP, IA-2, and the insulin-β 
chain (Table 2) to create T-cell lines for testing with standard and 
optimized tetramer staining protocols (Figure 2A) (see Figure S1 
in Supplementary Material for optimized protocol schematic). 
The control CMV line stained well with the pp65 tetramer under 
standard conditions with clear separation between the tetramerneg 
and tetramer+ cells (Figure 2B), which is characteristic of stand-
ard staining for many antiviral T-cell populations (22). Prior to 
cognate multimer staining, T-cell lines that had been stimulated 
with pancre atic β-cell-specific epitopes were assessed for reactiv-
ity against exogenously supplied peptides by measuring CD107a 
(58) and TNF (54) expression. No specific response was observed 
in lines stimulated with IGRP and IA2 peptides, and the lines 
were discarded. In contrast, the lines stimulated with insulin-β 
chain and GAD65 peptides expressed TNF/CD107a in response 
to cognate antigens (Figure 2C). These peptide-reactive T-cell 
lines were subsequently stained with irrelevant and cognate 
pancreatic peptide-HLA A*02:01 PE-conjugated tetramers. The 
percentage of tetramer+ cells increased when using the optimized 
protocol compared to the standard approach; in both cases, the 
optimized protocol resulted in approximately sixfold increase 
in the percentage of detected cells (Figure  2C). Importantly, 
the tetramer+ populations became more discernible from the 
tetramerneg cells when using the optimized protocol. Furthermore, 
the percentage of peptide-specific cells detected with the opti-
mized protocol correlated better with the functional response 
to exogenously supplied peptides, while standard tetramer 
staining vastly underestimated the fraction of peptide-reactive 
cells. Overall, the inclusion of two inexpensive reagents, the 
PKI Dasatinib and anti-fluorochrome Ab, to create an optimal 
tetramer staining protocol allowed autoimmune T-cells to be 
detected with relative ease.
Optimal Staining With pMHC Dextramers 
Further Improves the Detection  
of Autoimmune T-Cells
We next examined the PPI15–24 T-cell line grown as above. Even 
using the optimized tetramer staining protocol, we managed 
to detect only 10-fold less cells than detected in the parallel 
functional assay (Figure 3A). We then turned to using pMHC 
dextramers as we had previously demonstrated that these 
higher order reagents can extend the TCR affinity threshold that 
is amenable to pMHC multimer staining (Figure 1 and reagent 
schematic in Figure  3A) (22). Standard pMHC dextramer 
staining recovered a population of CD8 T-cells of similar size 
to that recovered with an optimized pMHC tetramer procedure 
FIGURE 3 | Detection of preproinsulin (PPI) T-cells is further improved using dextramers under optimal staining conditions. (A) Schematic representation of tetramers 
and dextramers showing the number of streptavidins (typically, 6–7 for dextramers), peptide–MHC (pMHCs), and phycoerythrins per unit of reagent. pMHC to 
streptavidin molar ratios of 4:1 and 3:1 were used to assemble tetramers and dextramers, respectively. T-cell receptor (TCR). (B) Sorted CD8 T-cells from a HLA 
A*02:01+ patient with type I diabetes were stimulated with a peptide from PPI (PPI15–24) and assessed 2 weeks later for reactivity against the PPI peptide (100 nM) by 
co-incubation with TAPI-0 and detection of CD107a and TNF. (C) The T-cells were also stained with irrelevant (hTERT540–548, ILAKFLHWL) or PPI tetramers (upper 
panel) and dextramers (lower panel) using standard (pMHC multimer alone) and optimal protocols (PKI + anti-PE Ab). The percentage of cells residing in each gate 
are shown. The red box indicates cells that were sorted by flow cytometry and shown in Figure 4.
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(Figure 3B). Use of the optimized procedure in conjunction with 
pMHC dextramer increased the size of the detected population 
by over 10-fold and brought it into line with the population size 
observed in the functional assay. While optimized dextramer 
staining vastly outperformed optimized tetramer staining in this 
case, the cells detected using the latter were fully functional. To 
formally prove functionality, we sorted cells that stained with 
optimized tetramer protocol and used them for further analysis 
(Figure 3C).
Optimally Tetramer-Sorted PPI-Specific 
T-Cell Clones Do Not Stain With a 
Standard pMHC Tetramer Protocol
Nearly all the cells (>90%) in the HLA A2-PPI15–24 tetramer-
enriched T-cell line stained with HLA A2-PPI15–24 tetramer 
when the optimized protocol containing PKI and cross-linking 
Ab was used. In parallel, the standard protocol that omitted 
these steps stained only 35% of this T-cell line, and with a low 
mean fluorescence intensity (Figure 4A). Over 70% of the cells 
in this T-cell line specifically responded to exogenously supplied 
PPI15–24 peptide indicating that roughly half of the functional 
T-cells could not be stained using standard pMHC tetramer 
staining (Figure 4B). We next subjected this enriched T-cell line 
to cloning by limiting dilution. Of the 34 T-cell clones generated, 
33 were responsive to PPI15–24 peptide. All 33 peptide-responsive 
T-cell clones stained well with HLA A2-PPI15–24 tetramer when 
the optimized protocol was used but failed to stain without addi-
tion of PKI and cross-linking Ab. An example staining for one 
clone, GD.PPI.1, is shown in Figure 4C. These results provide 
further evidence that standard pMHC tetramer staining fails 
to detect fully functional PPI-specific T-cells. Peptide titrations 
(data not shown) with these T-cell clones indicated that they 
required at least 100 nM exogenous PPI15–24 peptide in order to 
activate (Figure 4D). In order to determine whether such cells 
might be capable of responding to endogenously processed and 
presented peptide antigen we used “surrogate β-cell” K562 targets 
expressing both HLA A2 and PPI (42). T-cell clone GD.PPI.1 did 
not respond to K562 cells expressing HLA A2 alone but activated 
in response to these cells when they were also transduced with 
PPI (Figure 4D). We conclude that standard pMHC tetramer 
staining can fail to detect fully functional diabetogenic T-cells 
FIGURE 5 | Anti-fluorochrome magnetic microbeads enhance the staining of 
T-cells with tetramers. (A) The ability of a primary (1°) unconjugated 
anti-fluorochrome antibody (Ab) to stabilize tetramer was also tested in the 
form of Ab-conjugated magnetic microbeads. (B) HLA A*02:01-restricted 
Melanoma reactive clone CR.NLS.3 was stained with irrelevant ILAKFLHWL 
(hTERT540–548) and index NLSALGIFST [Insulin-like growth factor 2 mRNA 
binding protein 2 (IMP2367–376)], PE-conjugated tetramers using the conditions 
shown. All samples were treated with PKI apart from the standard conditions. 
The anti-PE magnetic microbeads were used as recommended by the 
manufacturer (Miltenyi Biotech), 20 µL per 100 µL of staining volume for up to 
1 × 107 cells, or bead volume dilutions thereof. The MFI of staining is shown 
for each condition.
FIGURE 4 | Optimal staining with preproinsulin (PPI) tetramers allowed 
functional T-cells to be isolated. Peripheral blood mononuclear cells (PBMCs) 
from a HLA A*02:01+ patient with type I diabetes were stimulated with PPI 
(PPI15–24) peptide (Figure 3A), which stained with PPI tetramer and dextramer 
under optimal conditions (PKI + anti-PE Ab). Tetramer+ cells were sorted by 
flow cytometry (Figure 3B) and expanded with PHA and irradiated allogeneic 
PBMCs. (A) The expanded cells were stained with irrelevant (ILAKFLHWL, 
hTERT540–548) and PPI tetramers using standard (tetramer alone) and optimal 
(as above) protocols. The percentage of cells residing in each gate is shown. 
(B) Reactivity of the enriched T-cells for PPI peptide was assessed by 
co-incubation with TAPI-0 and detection of CD107a and TNF. (C) Clone 
GD.PPI.1 grown from the enriched line was stained with irrelevant (hTERT) 
and PPI tetramers using standard and optimal protocols. The MFI of staining 
is shown on the histogram according to the key. (D) Overnight activation 
assay and MIP-1β enzyme-linked immunosorbent assay, with PHA as a 
positive control, PPI peptide (10 nM), and K562s transduced with genes for 
HLA A*02:01 (A2) ± PPI cDNA (PPI).
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capable of responding to endogenously expressed β-cell-specific 
proteins.
Optimized pMHC Multimer Staining Is 
Compatible With Magnetic-Bead-Based 
Cell Isolation
Flow cytometric sorting can be detrimental for T-cell fitness, and 
in some cases >98% of sorted cells fail to expand in culture (59). 
We have previously used an optimized protocol for isolating rare 
pMHCII-responsive CD4+ T-cells incorporating a magnetic bead 
enrichment step (60). These beads capture pMHC multimer+ 
cells via anti-fluorochrome Ab. We, therefore, reasoned that 
much of the improvement in T-cell recovery that we observed 
in our previous study (60) might have been due to stabilization 
of pMHC tetramer staining afforded by the anti-fluorochrome 
Ab-conjugated magnetic microbeads. We tested whether anti-
PE microbeads could enhance the ability to detect self-specific 
T-cells using a T-cell clone that requires an optimized protocol 
in order to stain with cognate (HLA A2-NLSALGIFST) tetramer 
(protocol schematic Figure S1 in Supplementary Material). 
If anti-fluorochrome magnetic bead-conjugated antibodies could 
be used to enhance staining with pMHC tetramers, this would 
provide a ready means for isolating cells without subjecting them 
to flow cytometric based sorting (Figure 5A). As expected, self-
reactive T-cell clone CR.NLS.3 failed to stain with cognate pMHC 
tetramer using standard conditions. Inclusion of PKI increased 
the staining intensity, which was further augmented by addition 
of anti-PE-conjugated magnetic beads (Figure 5B). The beads 
mediated a 7- to >11-fold enhancement, compared to a 13- to 
>18-fold improvement seen with soluble Ab (Figure 5B; Figure 
S2 in Supplementary Material), with increased bead volumes 
not improving the tetramer staining any further (Figure S2 in 
Supplementary Material). The improved effect with soluble Ab 
may reflect improved access and far lesser steric effects compared 
to bead-conjugated antibody. Overall, the protocol should allow 
magnetic sorting of tetramer+ cells without subjecting them to 
the rigors of flow cytometric sorting.
In light of the fact that magnetic anti-fluorochrome Ab could 
enhance pMHC multimer staining, we next used this protocol 
FIGURE 6 | Dextramers used with magnetic based purification allowed autoimmune T-cells to be isolated directly ex vivo. (A) Peripheral blood mononuclear cells 
from a HLA A*02:01+ patient with type I diabetes were treated with PKI and then stained with insulin-β chain10–18 (HLVEALYLV) PE-conjugated dextramers. Post 
staining the cells were labeled with anti-PE antibody-conjugated microbeads and magnetically enriched. T-cells were grown in vitro for 3 weeks then stained with 
PE-conjugated insulin-β chain tetramer and dextramers, with hTERT540–548 (ILAKFLHWL) multimers as an irrelevant control. Staining was performed under standard 
(multimer alone) or optimized (PKI + anti-PE Ab) conditions. The dotted line depicts the baseline for staining based on irrelevant multimers, with the percentage of 
cells staining above this shown for each condition. (B) The magnetically enriched T-cell line generated in A was tested for reactivity against insulin-β chain peptide by 
incubation with TAPI-0 and staining for TNF and CD107a. The percentage of cells residing in each gate is shown. (C,D) CD8 T-cells from an HLA A*02:01+A*24:02+ 
type 1 diabetes patient were enriched using the same approach shown in A, using either HLA A*24:02-PPI3–11 (LWMRLLPLL) dextramer (C) or HLA A*02:01-
IGRP265–273 (VLFGLGFAI) dextramer (D). Two weeks post expansion the cells were stained with their respective tetramers. hTERT tetramers were used as an 
irrelevant control. The percent of gated cells is shown and the mean fluorescence intensity for the PPI or IGRP staining displayed.
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to isolate and culture diabetogenic T-cells from the PBMC of 
another HLA A*0201 T1D patient. Patient PBMC were stained 
with insulin-β chain dextramer under optimal “bead” conditions, 
and purified cells were expanded using PHA and allogeneic 
PBMCs prior to further analyses. No staining was performed 
on the PBMC before sorting, as sample size was limited (5 × 106 
PBMCs). Limited cell number is commonplace for clinical 
samples due to distribution among research projects, and ethical 
guidelines on how much blood can be taken. The enriched line was 
87% dextramer+ using the optimal staining protocol, with cells 
also staining with dextramer under standard conditions (16%) 
and with the optimized tetramer protocol (29%) (Figure 6A). 
Staining was low/absent when using standard tetramer staining 
and suggested that very few, if any, antigen-specific T-cells would 
have been isolated if standard staining had initially been used. 
It might have been possible to isolate cells with optimal tetramer or 
FIGURE 7 | HLA B*27:05 vasoactive intestinal polypeptide receptor 1 (VIPR1) tetramers used with optimal staining conditions allowed autoimmune T-cells to be 
detected and isolated from patients with ankylosing spondylitis. (A) Peripheral blood mononuclear cells (PBMCs) from a HLA B*27:05 patient with ankylosing 
spondylitis were stained with irrelevant (HIV p24 gag263–272; KRWILLGLNK) and VIPR1400–408 (RRKWRRWHL) PE-conjugated tetramers directly ex vivo under standard 
(tetramer alone) and optimal (PKI + anti-PE Ab) conditions. (B) PBMCs for the same patient in A were PKI treated and stained with PE-conjugated VIPR1400–408 
tetramers then labeled with anti-PE antibody-conjugated microbeads for magnetic purification. After 3 weeks of culture, the line was stained with irrelevant (p24 gag) 
and VIPR1 tetramer under optimal staining conditions. (C) Using the same approach as in B from a second patient. Cells were stained 3 weeks post purification 
with irrelevant (HIV p24 gag263–272) and VIPR1400–408 tetramers using standard and optimal staining protocols.
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standard dextramer protocols but the optimal “bead” dextramer 
approach we applied gave a combination of superior staining and 
potential for magnetic enrichment. The T-cell line produced in 
this way showed specific reactivity for the Insulin-β chain pep-
tide (Figure 6B) confirming that the purification process using 
dextramers and magnetic beads had been successful. Similarly, 
PPI (residues 3–11, HLA A*24:02 restricted) and IGRP (residues 
265–273, HLA A*02:01 restricted)-specific T-cells were success-
fully enriched using dextramers and the optimal bead method for 
another patient. Subsequent staining of the cells with tetramers 
showed that PPI-specific T-cells could only be detected when the 
optimal protocol was used (Figure 6C). A less dramatic difference 
in terms of cell numbers between standard and optimized proto-
col was observed in case of the IGRP specific T-cells—however, 
the staining intensity was increased nearly fivefold in the latter 
case (Figure  6D). These results demonstrated that optimized 
pMHC multimer staining could be successfully combined with 
anti-fluorochrome Ab-conjugated beads to enable isolation and 
culturing of antigen-specific autoimmune T-cells. We next set 
out to apply this technique to obtain autoimmune T-cells from 
ankylosing spondylitis patients.
Optimal Staining and Isolation of Antigen-
Specific T-Cells From Ankylosing 
Spondylitis Patient Samples  
Using HLA B*27:05 Tetramers
Ankylosing spondylitis (AS) is a HLA B*27:05 associated 
autoimmune disease with characteristic inflammation of the 
joints and spine (61). HLA B*27:05 tetramers refolded with the 
RRKWRRWHL peptide (residues 400–408 from VIPR1) were 
used for ex vivo staining of a PBMC sample from an AS patient. 
There was a fivefold increase in VIPR1 tetramer staining using 
the optimal protocol (0.04%) compared to the standard approach 
(0.008%), with similar irrelevant tetramer staining for both con-
ditions (Figure 7A). Using optimal “bead” staining and magnetic 
separation, the VIPR1 tetramer+ cells were enriched to 9.7% when 
re-stained using the optimal protocol (Figure  7B). The same 
approach was used for a second AS patient (Figure 7C). Clones 
were obtained from both enriched lines by limiting dilution 
and characterized with VIPR1 tetramer. T-cell clones GD.AS69 
and GD.AS2 were grown from the line shown in Figure  7B. 
The GD.AS69 clone needed the optimal protocol to stain with 
FIGURE 8 | CD8 clones isolated from an ankylosing spondylitis patient using optimal tetramer staining are fully functional. (A) CD8 T-cell clones grown from T-cell 
lines (Figure 7) generated following tetramer enrichment using an optimal magnetic bead protocol (Figure 5). GD.AS69, GD.AS2, and GD.Russ2 were stained  
with HIV p24 gag263–272 (KRWILLGLNK) and VIPR1400–408 (RRKWRRWHL) PE-conjugated HLA B*27:05 tetramers, using standard (tetramer alone) and optimized 
(PKI + anti-PE Ab) protocols, according to the key. The MFI of staining is shown. (B) Functional testing of clones GD.AS69 and GD.AS2 using a TAPI-0 assay with 
CD107a and TNF Abs. Patient autologous lymphoblastoid cell line (LCL) was used to present HLA B*27:05 irrelevant peptide (DRASFIKNL from the α2 domain of 
collagen type VI114–122) and cognate VIPR1400–408 peptide (RRKWRRWHL). Autologous LCL were lentivirally transduced with genes for the α2 chain of collagen type VI 
(control protein) and vasoactive intestinal polypeptide receptor 1 (VIPR1) and used in the activation assay. Percentage reactivity is shown for the CD107a+ TNF+ gate.
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VIPR1 tetramer (Figure 8A). Conversely, clone GD.AS2 did stain 
under standard conditions but the optimal protocol substantially 
increased the intensity of staining (Figure 8A). Clone GD.Russ2, 
derived from the second donor, required the optimal protocol to 
stain with VIPR1 tetramer, similarly to GD.AS69 (Figure 8A). 
Clones GD.AS69 and GD.AS2 responded to exogenous VIPR 
peptide and were sufficiently sensitive to recognize an autologous 
B-cell line transduced to express the VIPR1 protein (Figure 8B). 
Thus, optimized pMHC multimer staining allowed successful 
culture and cloning of VIPR-reactive, HLA B*27:05-restricted 
T-cells. Two of three clones generated could not be stained with 
standard pMHC multimer staining protocol, and therefore, 
would not have been isolated without the optimized technique 
applied here.
DISCUSSION
Standard pMHCI Tetramer Staining Fails 
to Detect Antigen-Specific T-Cells  
With Low-Affinity TCRs
Peptide–MHC multimers are widely accepted as the “gold 
standard” for the detection and isolation of antigen-specific 
T-cells. As these reagents rely on physical detection, cognate cells 
can be detected without relying on any particular effector function. 
Physical detection of T-cells has some further advantages over 
functional detection as cells that are in the process of dividing 
would be unlikely, or unable, to respond by killing a target or 
secreting a lymphokine, and therefore, would remain undetect-
able. When used optimally, pMHC multimers usually detect a 
larger population of antigen-specific T-cells than responding 
cells in a functional assay. In keeping with this observation, 
we consistently found more antigen-specific cells with optimal 
pMHC multimer staining than were detected in parallel func-
tional assays. Accordingly, throughout our dataset, the fraction 
of T-cells detected with optimal pMHC multimer staining was 
higher than that detected in functional assays (detecting CD107a 
and/or TNF). Conversely, standard staining protocols detected a 
fraction of cells that was generally smaller than that revealed by 
functional assay confirming that some functional T-cells were not 
detected. These observations are in line with tetramer staining 
verses functional readouts using monoclonal T-cell populations 
where all cells might be expected to have capacity to respond 
to relatively high concentrations of exogenous cognate peptide. 
In parallel comparisons, 99.6% of the 1E6 T-cell clone stained 
with cognate tetramer while only 27 and 20% responded by 
intracellular staining for TNF in response to 1 µg/mL of cognate 
peptide or target cells expressing the cognate HLA A2 and PPI 
target, respectively (42). Similarly, 99% of GAD65-specific T-cell 
clone RK9C10 stained with pMHC tetramer while only 50.6 and 
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62% responded by intracellular TNF and surrogate degranula-
tion marker CD107a staining, respectively (56). We provide three 
further examples of parallel tetramer staining and activation of 
T-cell clones in Figure S3 in Supplementary Material, while all 
three clones exhibit >99% tetramer staining their activation with 
10 µM cognate peptide or real melanoma target cells ranges from 
52 to 83%. Thus, up to half of cognate T-cells that express TCR 
and that can be stained with pMHC multimer fail to respond in 
effector function assay.
The original pMHC multimer, a streptavidin-based pMHC 
tetramer (18), is still the most common form in use as it can be 
easily manufactured in-house (as here), or acquired via the NIH 
Tetramer Core Facility (Emory) or various commercial sources. 
Unfortunately, the TCR-pMHC affinity threshold amenable to 
detection by standard pMHC tetramer staining is higher than that 
required for efficient T-cell activation (21). Thus, these reagents 
can fail to detect fully functional T-cells with low-affinity TCRs 
and thereby underestimate the size of antigen-specific T-cell 
populations. This effect can be particularly pronounced for self-
reactive T-cells, or MHCII-restricted T-cells, where TCR–pMHC 
interactions are weaker (10). Indeed, several recent studies by 
different research groups have reported that, with some antigens, 
standard pMHC multimer staining can fail to stain the majority 
of antigen-specific T-cells (23, 33, 62). It has even been suggested 
that this discrepancy and the prominent use of pMHC staining 
for T-cell detection has biased T-cell immunology toward the 
type of T-cells that can be readily detected with these reagents 
because the important, low-affinity TCRs that can dominate 
antigen-specific T-cell responses are ignored (63, 64). The aim 
of this study was to compare the recovery of antigen-specific, 
self-reactive T-cells from patient samples using standard pMHC 
staining or an optimized protocol and to compare the results to 
functional assays for T-cell activation.
An Optimized pMHC Multimer Protocol 
Can Recover Autoimmune T-Cells
We have developed a variety of “tricks” in an attempt to circum-
vent the problem of unsuccessful staining of T-cells bearing weak 
affinity TCRs using the standard procedures (17, 20). The sim-
plest, and least expensive, of these improvements are the addition 
of PKI to prevent TCR triggering and downregulation (32) and 
the addition of an Ab (usually anti-fluorochrome) to cross-link 
the pMHC multimers (33). The advantages of these procedures 
are additive, and they can be applied with any pMHC multimer 
in all species tested to date for a cost of less than $0.05 per stain. 
Application of this optimized procedure in this study routinely 
detected an average of 40.5-fold (range 1.4- to 198-fold) more 
antigen-specific T-cells than parallel assays in the absence of PKI 
and anti-fluorochrome Ab. Whereas standard staining routinely 
discovered a smaller population of antigen-specific T-cells than 
could be detected in functional assays, the optimized protocol 
always detected more cells than parallel functional assays. As dis-
cussed above, the difference between the size of antigen-specific 
T-cell populations recovered by optimized pMHC tetramer stain-
ing and that revealed in functional assays might represent those 
cells that are undergoing cell division or happen to express a low 
level of TCR on their surface. We routinely observe that less cells 
respond functionally than stain with pMHC multimer even within 
clonal T-cells (Figure S3 in Supplementary Material). Overall, 
our results show that optimized protocols are substantially better 
at detecting self-reactive T-cells than standard protocols. The 
question remains whether the “optimal” protocol using pMHC 
dextramer + PKI + Ab recovers all the T-cells capable of respond-
ing to a given pMHC, or whether there are functional T-cells 
bearing TCRs too weak to be captured using even this optimized 
procedure.
Are Higher Order pMHC Multimers Better?
We have been asked this question many times since we compared 
staining with pMHC tetramers to that with pMHC dextramers 
in parallel assays and found that the higher order multimers, 
which carry more copies of both pMHC and fluorochrome per 
molecule, could recover CD4 and CD8 T-cells with weaker TCRs 
(22). Subsequently, Davis and colleagues showed that pMHC 
dodecamers, which incorporate 12 pMHC per molecule, stained 
twofold to fivefold more murine and human CD4 and CD8 
T-cells than detected in parallel assays with pMHC tetramers 
(23). These findings make it clear that, for T-cells with low-
affinity TCRs, higher order multimers can beat pMHC tetramers 
in head-to-head assays using the same conditions. However, the 
threshold of TCR affinity amenable to detection with pMHC 
tetramers with the optimal protocol used here is very low and 
below that found on the vast majority of cognate T-cells. We also 
find that an optimal staining with pMHC tetramer can recover 
cells that cannot be detected using standard pMHC dextramer 
protocols as currently listed on the Immudex website (March 
2018). We regularly see T-cells that can be stained with optimized 
pMHC tetramer staining that cannot be stained by standard 
pMHC dextramer staining in the absence of the PKI + Ab; this 
threshold is graphically depicted in Figure  1. The staining of 
the dextramer-sorted insulin-β line in Figure 6 provides a good 
example of these sensitivities; staining of this line was greatest 
using dextramer + PKI + Ab (87%) compared to 29, 16, and 2.3% 
for optimized tetramer staining, standard dextramer staining, 
and standard tetramer staining, respectively. Optimized pMHC 
tetramer staining was readily able to detect the PPI-specific 1E6 
T-cell clone when it was spiked into a PBMC samples (33); this 
T-cell is known to bear a very weak affinity TCR [KD > 240 μM 
(15, 65)]. Optimized pMHC tetramer staining can also recover 
the ILA1 T-cell clone from PBMC using the 5Y variant of the 
ILAKFLHWL hTERT-derived (41) peptide which similarly has 
a KD ~ 250 μM (33). Optimized pMHC tetramer staining with 
the 8E variant in this system, which is estimated to bind with 
KD ~ 2 mM (and >500 μM with certainty), did not recover the 
ILA1 T-cell in parallel experiments (33). The fact that optimized 
pMHC dextramer staining with the 8E variant can fully recover 
the ILA1 T-cell clone in parallel experiments provides some 
indication of where the threshold of detection for optimized 
pMHC tetramer and dextramer must lie. However, pMHC 
multimer binding thresholds are dependent on both TCR and 
CD8 expression levels so can vary with time for cultured cells, 
or if cells have recently encountered cognate antigen in vivo, so 
the above should only be taken as a rough estimate. In summary, 
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all but T-cells bearing the very weakest of cognate TCRs can be 
recovered using an optimized pMHC tetramer protocol. Thus, 
any pMHC multimer with 4 or more pMHC per molecule should 
be sufficient for almost all purposes providing an optimized 
protocol including PKI and cross-linking Ab is adopted, and we 
believe that the advantages afforded by higher order multimers 
will only rarely be required.
Are T-Cells With Very Low-Affinity TCRs 
Truly Functional?
It is becoming increasingly clear that optimized pMHC multimer 
staining procedures can stain T-cells with cognate TCRs that are 
far weaker than were previously believed to have any possibility of 
being functional. Consequently, it is worth asking two questions: 
(1) Can extremely weak TCR interactions trigger and activate 
T-cells? And (2) do low-affinity TCRs make a significant contribu-
tion to immunity? These important points will be addressed below.
Extremely Weak TCR Interactions Can Activate 
T-Cells
The best model system we are aware of for addressing this issue 
is the ILA1 T-cell/TCR, which recognizes the hTERT-derived 
peptide ILAKFLHWL (41). The ILA1 TCR refolds reason-
ably well to allow biophysical and structural studies with the 
soluble extracellular domain (66). As described above, the 5Y 
and 8E variants of ILAKFLHWL bind to the ILA1 TCR with 
KDs of >240 μM and >500 μM, respectively (21). The 5Y and 
8E variants of ILAKFLHWL act as reasonable agonists of the 
ILA1 T-cell; although these ligands are completely dependent 
on MHC interaction with the CD8 coreceptor (67). Thus, this 
model system suggests that extremely weak TCR interactions can 
activate T-cells. In the real world, the PPI peptide-specific 1E6 
TCR, identified in a patient T-cell that can kill human pancreatic 
β-cells (42), thus demonstrating responsiveness to natural target 
cells, has a TCR affinity of >240 μM (15, 65). In this study, we 
found that optimized pMHC tetramer staining recovered less 
T-cells from an insulin-β CD8 T-cell line than could be detected 
by functional assay (Figures  6A,B) and that standard pMHC 
dextramer staining only detected 35% of a PPI-specific T-cell 
line where >70% of T-cells responded to cognate peptide in a 
functional assay (Figure 4). The T-cells that responded to peptide 
but were not recovered using pMHC staining in these assays 
presumably express TCRs with extremely weak affinity for the 
cognate antigen. Based on the available evidence, we conclude 
that extremely weak TCR interactions can indeed activate T-cells 
but this does not prove that such T-cells are of biological relevance, 
particularly if they are competing for antigen in vivo with T-cells 
that have higher affinity TCRs.
Low-Affinity TCRs Make a Significant Contribution  
to Immunity
Our own data show that T-cells with low-affinity TCRs can func-
tion relatively poorly (12, 13, 21). These data fit with the general 
picture that has emerged from classic kinetic proofreading 
models of TCR triggering and T-cell activation (68, 69). Thus, 
there is now a general belief that T-cells that are most sensitive to 
antigen will bear the highest affinity TCRs and that these T-cells 
will, by definition, be avid binders of soluble pMHC multimers. 
The flipside of this viewpoint is that T-cells with weak affinity 
TCRs will be insensitive to peptide antigen and will be unlikely 
to play a dominant immune role in vivo. Our faith in the impor-
tance of TCR affinity and the emergence of pMHC tetramers as 
a gold standard for T-cell detection may have been responsible 
for study bias which underestimates the role of low-affinity TCRs 
(63). In the absence of definitive proof, assumptions that staining 
with pMHC multimer is a surrogate of how antigen-sensitive a 
given T-cell might be and of how effective and important it is 
in vivo are precarious. As discussed below, the view that T-cells 
with low-affinity TCRs are relatively insignificant during regular 
immune responses has softened over the last 8 years with murine 
studies showing first that low-affinity TCR interactions generate 
a complete immune response during the first week of infection 
with Listeria monocytogenes (70) through to recent data show-
ing that TCRs that escape negative selection and that cannot be 
stained with cognate pMHC tetramer have sufficient reactivity to 
cause disease in vivo (71).
Evidence From Humans and Other Primates
A recent video study that provided protocols for pMHCI staining of 
Simian Immunodeficiency Virus-specific CD8 T-cells in Rhesus 
Macaques showed that addition of 50 nM Dasatinib enhanced 
staining from 0.1% of CD8+ T-cells to 0.96% with a considerable 
concomitant increase in the MFI (34). Here, our demonstration 
that patient-derived T-cells with low-affinity TCRs can respond 
to relevant targets expressing endogenous antigen suggests that 
these cells have capacity to be relevant in  vivo. Furthermore, 
the 1E6 TCR isolated from a T1D patient, and capable of kill-
ing HLA A*02:01+ pancreatic β-cells in a glucose-dependent 
manner (42), has a low-affinity TCR (KD  >  240  μM). Other 
patient-derived TCRs that see different diabetogenic epitopes 
also bind with KD > 150 μM (manuscript in preparation) in line 
with suggestions that very weak TCRs are a common feature of 
autoimmune T-cells (10) (Figure 1). In accordance, a study of 
HLA DR-restricted responses to a type II collagen-derived pep-
tide in a patient with relapsing polychondritis found that patient 
PBMC contained T-cells that could be activated by this peptide 
or a plate-bound form of the pMHC but could not be detected 
by tetramer staining with this same pMHC; these results were 
confirmed using patient-derived T-cell clones and attributed to 
autoimmune TCR-pMHC interactions being weak (72).
We have also recently demonstrated that the dominant tumor- 
infiltrating lymphocyte-derived clonotypes in patient blood fol-
lowing successful “cure” (complete lasting remission) of Stage 
IV melanoma can only be detected by optimized pMHC mul-
timer staining (59). Clones expressing these TCRs were grown 
in culture and shown to kill autologous tumor but were only 
amenable to optimized pMHC multimer staining, suggesting that 
they bore TCRs with low-affinity for cognate antigen. These data 
strongly suggest that low-affinity TCRs substantially contribute to 
mediating remission during successful immunotherapy. We have 
also made the unexpected discovery that PBMC from the majority 
of EBV seropositive HLA A*02:01+ individuals contain functional 
CD8 T-cells specific for the immunodominant BMLF1-derived 
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epitope GLCTLVAML that can only be stained with the optimized 
procedure described here. PBMC from one individual made a 
strong response to GLCTLVAML peptide but showed very poor 
staining with pMHC tetramer in the absence of PKI and cross-
linking Ab (59). Optimized staining revealed a sizeable population 
of T-cells (0.15% of total CD3+ cells) that stained with high intensity. 
A clonal population of BMLF1-specific cells from this individual 
responded to 100 pM peptide and an autologous EBV-transformed 
B-cell line suggesting that these cells had capacity to exhibit strong 
potency in vivo (59). Davis and colleagues found that 10 nM pMHC 
dodecamer could recover a large population of CMV-specific 
T-cells from PBMC (1.76% of total T-cells); parallel staining with 
10 nM pMHC tetramer recovered a population 100 times smaller 
(0.017%) (23). Similarly, 10  nM dodecamer of the influenza 
A virus HA306–318 epitope HLA DR4-GGPKYVKQNTLKLAT 
recovered a population of cells comprising 0.92% of total T-cells 
compared to recovery of over fourfold less T-cells with pMHC 
tetramer even when used at 15 times higher concentrations (23). 
The authors conclude that “traditional tetramers may significantly 
underestimate the actual frequency of antigen-specific T-cells in the 
repertoire, which might be physiologically important in maintaining 
and mediating the effector function and homeostasis of the adaptive 
immune system.” In summary, increasing evidence suggest that 
human T-cells that bear weak TCRs that cannot be detected with 
standard pMHC tetramer staining play an important immune 
role. Nevertheless, it is impossible to definitively prove that these 
cells are important in vivo.
Evidence From Mice
Although there is abundant recent evidence demonstrating that 
low-affinity TCRs can make a profound contribution to immu-
nity, the counterview suggested in older studies is still prevalent. 
Unfortunately, most studies of TCR affinity and T-cell activation 
in mice have been undertaken in transgenic animals where all 
T-cells express a single, high-affinity TCR. Zehn and colleagues 
broke this mold by deliberately constructing a mouse expressing a 
TCR that barely escaped from negative selection (i.e., a TCR with 
affinity for self-antigen at the threshold of affinity that determines 
whether a T-cell is culled by negative selection or survives cen-
tral tolerance mechanisms) (71). The resultant low-affinity OT3 
T-cells are below the limit for reliable detection by conventional 
tetramer staining. However, OT3 T-cells, developed into func-
tional effector and memory T-cells, had sufficient reactivity to 
cause disease and could respond to ligands that bound with an 
affinity well below the affinity threshold for negative selection 
(71). These even weaker ligands would have almost certainly 
not stained OT3 T-cells with standard pMHC tetramer staining 
technology, yet they were capable of inducing acute activation 
in the periphery. This well-defined model of autoimmune 
T-cells in  vivo demonstrated that T-cells with extremely weak 
TCR–pMHC interactions, well below the threshold for pMHC 
multimer staining, can make a profound contribution to tissue 
destruction. Earlier studies, by Zehn et al., in the high-affinity 
OT1 transgenic model first gave hints that very weak TCR ligands 
could be functional and showed that such interactions were suf-
ficient to induce initial rapid expansion of naïve T-cells to gener-
ate effector and memory cells, thereby challenging the view that 
strong TCR–pMHC interaction were a prerequisite of CD8 T-cell 
activation (70). Even the V4 variant of the OT1 cognate OVA-
derived SIINFEKL peptide expanded OT1 cells in  vivo when 
delivered in recombinant L. monocytogenes (70). Remarkably, 
the OT1 TCR binds to the V4 variant with a KD of >1 mM by 
SPR (4); yet, this ligand could induce similar proliferation to the 
wild-type OVA ligand over 6–7 division cycles and produce cells 
with a similar effector phenotype 1 week after infection despite 
having an affinity well below the threshold for negative selection 
(70). The only major difference observed between a strong TCR 
stimulus and an extremely weak stimulus occurred at later time 
points and affected the length of the expansion period and the 
concomitant burst size (i.e., responses induced by very weak TCR 
ligands were curtailed). Despite the difference in burst size, the 
primed T-cells developed into memory cells that were compara-
ble after adoptive transfer and challenge with L. monocytogenes 
expressing wild-type SIINFEKL sequence indicating that recall 
expansion was independent of the priming antigen stimuli (70).
Despite the compelling data described above, showing that 
low-affinity TCR–pMHC interactions can be extremely relevant 
in vivo, these transgenic models may bear little relevance to the 
real-world situation where polyclonal T-cell populations compete 
with each other for limited antigen. Evidence that TCR affinity 
may set the basal activity of T-cells by regulating the expression 
of restricting phosphatases such as SHP-1 (73), suggests that any 
preference for high-affinity TCRs could be offset by counterbal-
ancing mechanisms that “level the playing field” and allow weak 
affinity TCRs to compete with their more avid counterparts. 
Recent data from Evavold and colleagues examining six different 
polyclonal CD4 T-cell responses in mice challenges the notion 
that T-cells with high-affinity TCRs, which are amenable to detec-
tion with standard pMHC tetramer technology, are the major 
responders during primary immune responses (64). Instead, 
these data show that T-cells that stain by standard tetramer tech-
nology comprise just 5–30% of the total antigen-specific naïve 
murine T-cell repertoire. A study of TCR diversity and T-cell 
sensitivity in humanized HLA DR4 mice immunized with the 
human cartilage gp-39263–275 epitope uncovered great variability 
in the ability of HLA DR4-gp-39263–275 tetramers to stain cog-
nate hybridomas. Over 30% of the hybridomas that responded 
to cognate antigen could not be tetramer stained leading the 
authors to suggest that “immune responses that are dominated 
by relatively low-affinity TCR interactions, such as those that 
may occur in autoimmune disease, will be difficult to detect using 
standard tetramer techniques” (74). Mass cytometry (CyTOF) 
experiments using 5C.C7 T-cells which bear a low-affinity TCR 
(75) support conclusions that pMHC tetramers fail to detect the 
majority of antigen-specific T-cells by showing that that a major 
population of tetramer-negative T-cells that only stained with 
higher order dodecamer, exhibited equal functionality to T-cells 
that stained with tetramer. Additional studies from the Evavold 
laboratory have demonstrated that pMHCII tetramer staining 
underestimated the H2-IAb-restricted CD4+ T-cell population 
specific for lymphocytic choriomeningitis virus glycoprotein61–80 
by fourfold and the H2-IAb-restricted population specific for 
myelin oligodendrocyte glycoprotein35–55 by eightfold (62). 
In summary, the most recent in  vivo studies lend full support 
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to the notion that completely functional and important T-cell 
responses can remain “below the radar” when it comes to detec-
tion by the “gold standard” of pMHC tetramer staining.
Optimized pMHC Multimer Staining  
Is Compatible With Bead-Based  
Magnetic Sorting
The generation of autoimmune T-cells lines for this study greatly 
benefited from our discovery that anti-PE Ab-conjugated to 
magnetic beads improved pMHC multimer staining in much the 
same way as we have demonstrated for soluble anti-fluorochrome 
antibodies (33). This fortuitous effect then allowed magnetic 
sorting and culturing of T-cells that had TCRs that were below 
the threshold for staining by standard pMHC tetramer technol-
ogy. Curiously, we previously used a technique involving such 
a magnetic bead step for the detection of antiviral CD4 T-cells 
(60). This technique appears to have become widely adopted 
for the characterization of CD4 T  cells by pMHCII tetramers 
although most studies have not shown staining with and without 
the inclusion of beads, meaning that it is not possible to compare 
the intensity of staining generated with and without bead inclu-
sion. Nevertheless, early studies using magnetic bead enrichment 
did show staining of samples before and after bead enrichment. 
Revisitation of these data in light of our discovery that anti-
fluorochrome antibody-conjugated magnetic beads can stabilize 
pMHC multimer staining is revealing. A study of CD4 T-cells 
in nonobese diabetic mice used two different pMHCII tetramers 
to stain samples from peptide immunized mice before and after 
bead enrichment (76). Throughout this study, it is evident that the 
cells recovered with these reagents after enrichment with anti-PE 
magnetic beads exhibited a higher MFI than parallel samples 
without the enrichment (76). Magnetic bead enrichment was 
also used for the analysis of CD4 T-cells specific for the Hepatitis 
C virus directly ex vivo in patient PBMC (77). The inclusion of 
the magnetic bead step substantially aided the recovery of T-cells. 
Reanalysis of these data also shows that cells that underwent the 
procedure with anti-PE magnetic beads stained with higher MFI 
than staining without these beads (77). Presumably, the beads 
acted to stabilize the pMHC during final washing steps and flow 
cytometry as we have demonstrated for soluble anti-PE Ab (33). 
Our discovery in this study that anti-PE magnetic beads improve 
the staining of T-cells with low-affinity TCRs now suggests that 
part of the improved staining researchers observed over a decade 
ago was due to the effect we describe here. Indeed, had the anti-
PE beads been added earlier in the protocol, it is likely that the 
enhancement effect would have been even more pronounced. The 
inclusion of anti-fluorochrome magnetic beads also improved the 
MFI of staining in a further study from the Klenerman labora-
tory that used HLA-DR-HA306–318 to stain PBMC directly ex vivo 
(78). Anti-fluorochrome magnetic beads have also had a positive 
effect on the recovery of CD8 T-cells with pMHC tetramers (79). 
Indeed, close scrutiny of these data from Barnes et al. (79) show 
that inclusion of the beads enhanced the MFI of pMHC tetramer 
staining and cleaned up the “tail” of tetramerlow cells to give clean 
populations of CD8 T-cells specific for EBV, parvovirus, and CMV. 
Although there is improvement of pMHC multimer staining with 
cross-linking Ab beads regardless of the TCR affinity, this effect 
is likely to be greatest when the TCR affinity is low and the TCR-
pMHC dwell time is short (33). The ability to stain, magnetically 
sort, and successfully culture T-cells with low-affinity TCRs as we 
have done here should aid future study of such cells.
Summary
Mounting evidence now challenges the view that only T-cells with 
relatively high-affinity TCRs play a prominent role in immunity. 
This is especially true for self-antigens where T-cells with the 
strongest TCRs are eliminated by central and peripheral tolerance 
mechanisms. Anticancer and autoimmune TCRs can bind to their 
cognate pMHC with very low affinities that often fall below the 
threshold compliant with standard pMHC multimer staining. 
The inexpensive and easily applied optimization methodology 
we describe here enables recovery of fully functional, self-reactive 
T-cells with extremely low TCR affinities. It remains to be seen 
whether the lower TCR-pMHC affinity threshold that can be 
detected by the optimized pMHC multimer technology is sufficient 
to encapsulate all T-cells that are capable of mounting a functional 
response to antigen. Nevertheless, we strongly recommend that 
researchers apply these techniques, and where possible also assay 
T-cell function, to avoid underestimating the size of antigen-specific 
T-cell populations and the diversity of antigen-specific TCRs.
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